According to the new market research report “Metabolomics Market by Product (GC,UPLC, CE, Surface based Mass Analysis), Application (Biomarker Discovery, Drug Discovery, Functional Genomics), Indication (Cardiology, Oncology, Inborn Errors), End User (Academic Institute, CROs) – Global Forecast to 2025“, published by MarketsandMarkets™, is projected to reach USD 4.1 billion by 2025, at a CAGR of 13.4% between 2020 and 2025.
Recent Developments in Metabolomics Technology Market:
# In 2020, Danaher Corporation acquired GE Healthcare’s Life Sciences business.
# In 2020, Agilent and Thermo Fisher extended their agreement to enhance the compatibility of Thermo Fisher’s analytical systems with Agilent’s OpenLAb Chromatography Data System
# In 2020, Waters Corporation announced the establishment of Immerse Cambridge, a research laboratory in the heart of Cambridge’s Kendall Square. Immerse Cambridge will serve as a strategic, collaborative space in the community, where Waters can partner with academia and research to accelerate the next generation of scientific advancements.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=900
The major factors driving the growth of this market are the growing R&D expenditure in the pharmaceutical & biopharmaceutical industry, growing demand for personalized medicine and increasing use of metabolomics in toxicology testing are driving the growth of the global metabolomics industry.
Separation tools accounted for the largest share in the metabolomics market in 2019.
Based on the product & service, the market is categorized into metabolomics instruments and bioinformatics tools and services. The metabolomics instruments segment is further categorized into separation tools and detection tools. Separation tools is sub segmented into gas chromatography, high-performance liquid chromatography, ultra-performance liquid chromatography, and capillary electrophoresis. Similarly, detection tools are categorized into nuclear magnetic resonance (NMR) spectroscopy, mass spectrometry (MS), and surface-based mass analysis. The separation tools segment accounted for the largest share of the market in 2019. The widespread use of separation tools in research activities, increase in funds for research projects, development of innovative technologies in these tools, and their extensive application in the drug discovery process are fueling the growth of this segment.
Cancer accounted for the largest share in the market in 2019
Based on indication, the metabolomics market has been segmented into into cancer, cardiovascular disorders, neurological disorders, metabolic disorders, inborn errors of metabolism, and other indications. The cancer segment is expected to account for the largest market share in 2020, with the highest growth rate as well. This can primarily be attributed to the growing use of metabolomics in cancer research and increasing number of cancer patients.
Academic and research institutes accounted for the largest share the metabolomics technology market in 2019
Based on end user, the market has been segmented into academic and research institutes, pharmaceutical & biotechnology companies, contract research organizations, and other end users. The academic and research institutes segment accounted for the largest share of the market in 2019. The increasing number of research activities in the field of metabolomics and funding to the academic and research institutes to conduct metabolomics research are the factors responsible for the largest share of the segment.
Biomarker Discovery accounted for the largest share of the metabolomics market
Based on application, the market has been segmented into biomarker discovery, drug discovery, toxicology testing, nutrigenomics, functional genomics, personalized medicine, and other applications. Biomarker discovery accounted for the largest share of the market in 2019. The growing implications of metabolic biomarkers to access the pathophysiological health status of patients are expected to drive market growth.
Request Sample Pages:
https://www.marketsandmarkets.com/requestsampleNew.asp?id=900
North America accounted for the largest share of the metabolomics market in 2019.
Based on the region, the global market is segmented into North America, Europe, the Asia Pacific, Latin Ametica and Middle East & Africa. In 2019, North America accounted for the largest share of the metabolomics technologies market. The large share of the North America region can be attributed to the presence of major players operating in the market in the US, growing biomedical research in the US, and rising preclinical activities by CROs and pharmaceutical companies in the region.
The metabolomics market is dominated by a few globally established players such as Waters Corporation (US), Agilent Technologies (US), Shimadzu Corporation (Japan), Thermo Fisher Scientific (US), Danaher Corporation (US), Bruker Corporation (US), PerkinElmer (US), Merck KGaA (Germany), GE Healthcare (US), Hitachi High-Technologies Corporation (Japan), Human Metabolome Technologies, Inc. (Japan), LECO Corporation (US), Metabolon, Inc. (US), Bio-Rad Laboratories (US), Scion Instruments (US), DANI Instruments S.p.A. (Italy), GL Sciences (Japan), SRI Instruments (US), Kore Technology Ltd. (UK), and JASCO, Inc. (US) among others.
The Global Metabolomics Market research study involved extensive use of secondary sources, directories, and databases to identify and collect information and in-depth interviews were conducted with various primary respondents, including key industry participants, subject matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify critical qualitative and quantitative information, and to assess market prospects.According MarketsandMarkets™ Research – The report “Metabolomics Market by Product (GC,UPLC, CE, Surface based Mass Analysis), Application (Biomarker Discovery, Drug Discovery,Functional Genomics), Indication (Cardiology, Oncology,Inborn Errors), End User (Academic Institute,CROs) – Global Forecast to 2025” The global metabolomics technology market size is projected to reach USD 4.1 billion by 2025, at a CAGR of 13.4% between 2020 and 2025The major factors driving the growth of this market are the growing R expenditure in the pharmaceutical & biopharmaceutical industry, growing demand for personalized medicine and increasing use of metabolomics in toxicology testing are driving the growth of the global metabolomics industry.Request Research Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=900Growth Driver: Availability of government and private funding for metabolomics research;Metabolomic studies are gaining prominence in the life science industry as they help reveal the optimum level of specific metabolites associated with the onset/progression of a disease and the exposure or response to treatment.
As metabolomics is considered a novel approach with tremendous potential, additional research is being conducted in this field.
Also, in recent years, the focus on metabolomic biomarkers has increased in drug development.
As a result of these factors, government and private investments in metabolomics research is increasing.According to a report by The Metabolomics Innovation Centre (TMIC), metabolomics has experienced tremendous growth since the last decade.
High-impact metabolomic discoveries in several diseases, such as cancer, have increased investments in metabolomics facilities across the globe.Opportunity:Biomarker development;Metabolomics is used to identify new biomarkers through bioinformatics tools, which indicate the changes in the physiological state of a cell or tissue.
As a result of these technological developments, new biomarkers are being regularly discovered.
